Mangoceuticals, Inc. (MGRX) NASDAQ
0.38
-0.0372(-8.85%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.38
-0.0372(-8.85%)
Currency In USD
| Previous Close | 0.42 |
| Open | 0.41 |
| Day High | 0.42 |
| Day Low | 0.38 |
| 52-Week High | 2.75 |
| 52-Week Low | 0.16 |
| Volume | 961,262 |
| Average Volume | 6.55M |
| Market Cap | 3.88M |
| PE | -0.3 |
| EPS | -1.27 |
| Moving Average 50 Days | 0.39 |
| Moving Average 200 Days | 1.09 |
| Change | -0.04 |
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
GlobeNewswire Inc.
Mar 06, 2026 9:00 PM GMT
Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and Pe
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
GlobeNewswire Inc.
Feb 23, 2026 9:05 PM GMT
Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and Pea
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
GlobeNewswire Inc.
Feb 19, 2026 9:05 PM GMT
Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on developing, marketing, and sel